» Articles » PMID: 32547333

Nonlinear Dose-Response Modeling of High-Throughput Screening Data Using an Evolutionary Algorithm

Overview
Journal Dose Response
Publisher Sage Publications
Date 2020 Jun 18
PMID 32547333
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Nonlinear dose-response relationships exist extensively in the cellular, biochemical, and physiologic processes that are affected by varying levels of biological, chemical, or radiation stress. Modeling such responses is a crucial component of toxicity testing and chemical screening. Traditional model fitting methods such as nonlinear least squares (NLS) are very sensitive to initial parameter values and often had convergence failure. The use of evolutionary algorithms (EAs) has been proposed to address many of the limitations of traditional approaches, but previous methods have been limited in the types of models they can fit. Therefore, we propose the use of an EA for dose-response modeling for a range of potential response model functional forms. This new method can not only fit the most commonly used nonlinear dose-response models (eg, exponential models and 3-, 4-, and 5-parameter logistic models) but also select the best model if no model assumption is made, which is especially useful in the case of high-throughput curve fitting. Compared with NLS, the new method provides stable and robust solutions without sensitivity to initial values.

Citing Articles

Extending the lymphoblastoid cell line model for drug combination pharmacogenomics.

Green A, Anchang B, Akhtari F, Reif D, Motsinger-Reif A Pharmacogenomics. 2021; 22(9):543-551.

PMID: 34044623 PMC: 8212852. DOI: 10.2217/pgs-2020-0160.

References
1.
Colbert T, Till B, Tompa R, Reynolds S, Steine M, Yeung A . High-throughput screening for induced point mutations. Plant Physiol. 2001; 126(2):480-4. PMC: 1540114. DOI: 10.1104/pp.126.2.480. View

2.
Holbeck S, Camalier R, Crowell J, Govindharajulu J, Hollingshead M, Anderson L . The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic Activity. Cancer Res. 2017; 77(13):3564-3576. PMC: 5499996. DOI: 10.1158/0008-5472.CAN-17-0489. View

3.
Hegi M, Diserens A, Gorlia T, Hamou M, De Tribolet N, Weller M . MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352(10):997-1003. DOI: 10.1056/NEJMoa043331. View

4.
Cedergreen N, Ritz C, Streibig J . Improved empirical models describing hormesis. Environ Toxicol Chem. 2006; 24(12):3166-72. DOI: 10.1897/05-014r.1. View

5.
Wu G, Doberstein S . HTS technologies in biopharmaceutical discovery. Drug Discov Today. 2006; 11(15-16):718-24. DOI: 10.1016/j.drudis.2006.06.010. View